How have PRTC shares performed in 2024?

PureTech Health's stock was trading at $28.18 at the beginning of 2024. Since then, PRTC shares have decreased by 4.4% and is now trading at $26.9350. View the best growth stocks for 2024 here .

When is PureTech Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our PRTC earnings forecast .

How do I buy shares of PureTech Health?

Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRTC

PureTech Health (PRTC) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free PRTC Stock Alerts

$26.94

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $26.94
▼
$26.94
50-Day Range: $22.05
▼
$30.91
52-Week Range: $17.08
▼
$34.00

Volume: 228 shs
Average Volume: 3,423 shs
Market Capitalization: $727.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Ownership SEC Filings Short Interest Social Media

Get PureTech Health alerts:

PureTech Health MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.02% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.23
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.67) to ($3.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.12 out of 5 stars

Medical Sector

905th out of 918 stocks

Pharmaceutical Preparations Industry

420th out of 426 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for PureTech Health.

3.0

Short Interest

Percentage of Shares Shorted
0.02% of the outstanding shares of PureTech Health have been sold short.
Short Interest Ratio / Days to Cover
PureTech Health has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in PureTech Health has recently increased by 16.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
PureTech Health does not currently pay a dividend.
Dividend Growth
PureTech Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRTC.

1.8

News and Social Media Coverage

News Sentiment
PureTech Health has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for PureTech Health this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for PRTC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PureTech Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.30% of the stock of PureTech Health is held by insiders.
Percentage Held by Institutions
Only 0.04% of the stock of PureTech Health is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for PureTech Health are expected to grow in the coming year, from ($4.67) to ($3.65) per share.
Price to Book Value per Share Ratio
PureTech Health has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About PureTech Health Stock (NASDAQ:PRTC)

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PRTC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRTC Stock News Headlines

April 18, 2024 | businesswire.com

PureTech Health: Notice of Results

April 16, 2024 | finance.yahoo.com

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 14, 2024 | americanbankingnews.com

PureTech Health (NASDAQ:PRTC) Shares Gap Down to $27.93

April 12, 2024 | americanbankingnews.com

PureTech Health (NASDAQ:PRTC) Sees Large Volume Increase

April 11, 2024 | lse.co.uk

US FDA hands fast track to PureTech head and neck cancer treatment

April 11, 2024 | markets.businessinsider.com

PureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck Cancers

April 11, 2024 | businesswire.com

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

April 19, 2024 | Insiders Exposed (Ad)

This consistently signaled gains of 453%... 610%... and even 1036%...

April 9, 2024 | businesswire.com

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

March 18, 2024 | businesswire.com

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

March 13, 2024 | finance.yahoo.com

PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia

February 28, 2024 | finance.yahoo.com

AKLI Mar 2024 3.000 call

February 27, 2024 | lse.co.uk

PureTech notes positive results from Shionogi's EndeavorRx ADHD trial

February 27, 2024 | finance.yahoo.com

PureTech to Present at Two Upcoming Investor Conferences

February 27, 2024 | businesswire.com

PureTech to Present at Two Upcoming Investor Conferences

February 27, 2024 | finance.yahoo.com

PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan

February 27, 2024 | businesswire.com

PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan

February 22, 2024 | finance.yahoo.com

PureTech Health plc (PRTC)

February 15, 2024 | finance.yahoo.com

Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround

February 9, 2024 | fool.co.uk

LSE:PRTC (PureTech Health plc)

January 23, 2024 | seekingalpha.com

PRTC PureTech Health plc

December 20, 2023 | msn.com

PureTech outlook for 2024

December 7, 2023 | finance.yahoo.com

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

November 14, 2023 | msn.com

PureTech Phase 2 study for anti-anxiety drug LYT-300 meets primary endpoint

October 11, 2023 | finance.yahoo.com

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting

October 6, 2023 | bizjournals.com

At Women Who Lead in Life Sciences, female leaders got the spotlight [PHOTOS]

See More Headlines

Receive PRTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 4/26/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRTC
CUSIP: N/A
CIK: 1782999
Web: www.puretechhealth.com
Phone: 617-482-2333
Fax: 617-482-3337
Employees: 111
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $15.62 million
Price / Sales: 46.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $19.64 per share
Price / Book: 1.37

Miscellaneous

Outstanding Shares: 27,000,000
Free Float: 25,564,000
Market Cap: $727.25 million
Optionable: Not Optionable
Beta: 1.23

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Spencer Ball
Senior Vice President of Human Resources
Ms. Aleksandra Filipovic M.D.
Ph.D., Head of Oncology
Ms. Cheryl Murphy Ph.D.
Head of Grants Management & Strategy
Ms. Anita Terpstra J.D.
Ph.D., Senior VP & Head of Intellectual Property
Mr. Dilip Kodira
Head of Data Science
Ms. Anne Burkhardt Ph.D.
Head of Research
Dr. Julie Krop M.D. (Age 58)
Chief Medical Officer
Ms. Joy Bauer M.S.
RDN, Chief Nutrition Officer
Mr. Robert Lyne (Age 41)
Chief Portfolio Officer
Mr. William Berry CPA
Controller

Key Competitors

View All Competitors

PRTC Stock Analysis - Frequently Asked Questions

How have PRTC shares performed in 2024?: PureTech Health's stock was trading at $28.18 at the beginning of 2024. Since then, PRTC shares have decreased by 4.4% and is now trading at $26.9350.
View the best growth stocks for 2024 here.
When is PureTech Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our PRTC earnings forecast.
How do I buy shares of PureTech Health?: Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial